{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:25:23Z","timestamp":1790400323080,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1642,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Academic Promotion Programme of Shandong First Medical University","award":["2019QL017"],"award-info":[{"award-number":["2019QL017"]}]},{"name":"Shandong Provincial Medical and Health Science and Technology Development Plan","award":["2018WS120"],"award-info":[{"award-number":["2018WS120"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sacubitril\/valsartan significantly reduced heart failure (HF) hospitalization and cardiovascular mortality in a randomized controlled trial. However, little is known about real-world efficacy and safety of sacubitril\/valsartan in Chinese patients with HF with reduced ejection fraction (HFrEF). We aimed to evaluate whether sacubitril\/valsartan could improve cardiac function in Chinese patients with HFrEF in a tertiary hospital in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients with HFrEF receiving sacubitril\/valsartan in our hospital between January 2018 and January 2020 were recruited in the present study. We retrospectively collected and analysed all clinical parameters at baseline and during follow-up. A total of 100 consecutive patients (73% male) with HFrEF were recruited in the present study. During a median follow-up period of 365 days [interquartile range (IQR), 346\u2013378], a pronounced improvement of cardiac function was achieved. New York Heart Association classification was significantly improved (P &amp;lt; 0.001), and median N-terminal pro-B-type natriuretic peptides level significantly decreased from 3003 pg\/mL (IQR, 1513\u20135404) to 2039 pg\/mL (IQR, 921\u20133955) (P = 0.010). Mean left ventricular ejection fraction increased from 31 \u00b1 6% to 38 \u00b1 10% (P &amp;lt; 0.001) and median left ventricular end-diastolic diameter reduced from 63 mm (IQR, 59\u201367) to 60 mm (IQR, 55\u201368) (P = 0.001). Mean pulmonary arterial systolic pressure decreased significantly from 49 \u00b1 13 mmHg to 44 \u00b1 12 mmHg (P &amp;lt; 0.001) and median right ventricular end-diastolic diameter reduced from 23 mm (IQR, 21\u201326) to 22 mm (IQR, 20\u201325) (P = 0.030). After treatment with sacubitril\/valsartan, mean estimated glomerular filtration rate significantly decreased (from 88.8 \u00b1 22.4 mL\/min to 71.8 \u00b1 27.3 mL\/min, P &amp;lt; 0.001). Median serum creatinine and median blood urea nitrogen levels significantly increased [from 0.9 mg\/dL (IQR, 0.8\u20131.0) to 1.1 mg\/dL (IQR, 0.9\u20131.3), P &amp;lt; 0.001, and from 6.8 mmol\/L (IQR, 5.5\u20138.9) to 8.0 mmol\/L (IQR, 6.6\u201310.3), P = 0.002, respectively]. The proportion of patients with chronic kidney disease Stage 3\/4 increased significantly from 8% to 39% (P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Chinese patients with HFrEF, sacubitril\/valsartan treatment was associated with a pronounced improvement of cardiac function, but might be prone to a decrease in blood pressure and deterioration in renal function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13491","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:50:31Z","timestamp":1624337431000},"page":"3783-3790","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Sacubitril\/Valsartan Improves Cardiac Function in Chinese Patients with Heart Failure: A Real-World Study"],"prefix":"10.1093","volume":"8","author":[{"given":"Wenwen","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, the Second Affiliated Hospital of Shandong First Medical University , 366 Taishan Street, Tai'an, 271000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Second Affiliated Hospital of Shandong First Medical University , 366 Taishan Street, Tai'an, 271000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, the Second Affiliated Hospital of Shandong First Medical University , 366 Taishan Street, Tai'an, 271000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heqin","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Second Affiliated Hospital of Shandong First Medical University , 366 Taishan Street, Tai'an, 271000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"2026012114230105600_ehf213491-bib-0001","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114230105600_ehf213491-bib-0002","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114230105600_ehf213491-bib-0003","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012114230105600_ehf213491-bib-0004","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ehf2.12258","article-title":"Insights into implementation of sacubitril\/valsartan into clinical practice","volume":"5","author":"Martens","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012114230105600_ehf213491-bib-0005","first-page":"108","article-title":"Ejection fraction improvement and reverse remodeling achieved with sacubitril\/valsartan in heart failure with reduced ejection fraction patients","volume":"7","author":"Almufleh","year":"2017","journal-title":"Am J Cardiovasc Dis"},{"key":"2026012114230105600_ehf213491-bib-0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/03007995.2019.1576481","article-title":"Sacubitril\/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction","volume":"35","author":"Cosentino","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026012114230105600_ehf213491-bib-0007","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12435","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction","volume":"36","author":"Martens","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"2026012114230105600_ehf213491-bib-0008","first-page":"102","article-title":"Hospitalization cost reduction with sacubitril\u2013valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry","volume":"22","author":"Correale","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026012114230105600_ehf213491-bib-0009","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114230105600_ehf213491-bib-0010","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/ejhf.634","article-title":"PARADIGM-HF: does dose matter?","volume":"18","author":"Cleland","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114230105600_ehf213491-bib-0011","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation","volume":"74","author":"Chang","year":"2019","journal-title":"J Cardiol"},{"key":"2026012114230105600_ehf213491-bib-0012","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ejhf.1054","article-title":"Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril\/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study","volume":"20","author":"Senni","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114230105600_ehf213491-bib-0013","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2018.12.063","article-title":"Effect of neprilysin inhibition on various natriuretic peptide assays","volume":"73","author":"Ibrahim","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012114230105600_ehf213491-bib-0014","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-type natriuretic peptide during treatment with sacubitril\/valsartan: the PARADIGM-HF trial","volume":"73","author":"Myhre","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012114230105600_ehf213491-bib-0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril\u2013valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2026012114230105600_ehf213491-bib-0016","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10557-019-06858-0","article-title":"Sacubitril\/valsartan in real-life practice: experience in patients with advanced heart failure and systematic review","volume":"33","author":"Moliner-Ab\u00f3s","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012114230105600_ehf213491-bib-0017","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.3390\/jcm8122165","article-title":"The effects of sacubitril\/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure with reduced ejection fraction: the \u201chemodynamic recovery\u201d","volume":"8","author":"Romano","year":"2019","journal-title":"J Clin Med"},{"key":"2026012114230105600_ehf213491-bib-0018","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2217\/cer-2019-0014","article-title":"Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril\/valsartan initiation in daily practice","volume":"8","author":"Morillas-Climent","year":"2019","journal-title":"J Comp Eff Res"},{"key":"2026012114230105600_ehf213491-bib-0019","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FJC.0000000000000641","article-title":"Sacubitril\/valsartan in daily clinical practice: data from a prospective registry","volume":"73","author":"Vicent","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012114230105600_ehf213491-bib-0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jjcc.2019.08.005","article-title":"Recovery of left ventricular dysfunction after sacubitril\/valsartan: predictors and management","volume":"75","author":"Chang","year":"2020","journal-title":"J Cardiol"},{"key":"2026012114230105600_ehf213491-bib-0021","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction","author":"Martens","journal-title":"Cardiovas Ther"},{"key":"2026012114230105600_ehf213491-bib-0022","first-page":"1","article-title":"Sacubitril\/valsartan in daily clinical practice: data from a prospective registry","volume":"73","author":"Vicent","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012114230105600_ehf213491-bib-0023","first-page":"108","article-title":"Original article ejection fraction improvement and reverse remodeling achieved with sacubitril\/valsartan in heart failure with reduced ejection fraction patients","volume":"7","author":"Almufleh","year":"2017","journal-title":"Am J Cardiovasc Dis"},{"key":"2026012114230105600_ehf213491-bib-0024","article-title":"Sacubitril\/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: the Daunia Heart Failure Registry","volume":"27","author":"Correale","year":"2020","journal-title":"IJC Heart Vasc"},{"key":"2026012114230105600_ehf213491-bib-0025","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026012114230105600_ehf213491-bib-0026","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3390\/jcm8101582","article-title":"Impact of sacubitril\/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients","volume":"8","author":"El-Battrawy","year":"2019","journal-title":"J Clin Med"},{"key":"2026012114230105600_ehf213491-bib-0027","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1074248419872958","article-title":"Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: real-world experience from Taiwan","volume":"25","author":"Hsiao","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026012114230105600_ehf213491-bib-0028","doi-asserted-by":"crossref","first-page":"113","DOI":"10.31083\/j.rcm.2020.01.2","article-title":"LCZ696 and preservation of renal function in heart failure: a meta-analysis of 6 randomized trials","volume":"21","author":"Chen","year":"2020","journal-title":"Rev Cardiovasc Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13491","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/5\/3783\/65567791\/eschf_8_5_3783.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/5\/3783\/65567791\/eschf_8_5_3783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:28:53Z","timestamp":1769023733000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/5\/3783\/8345921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,6,22]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13491","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10]]},"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"2020-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}